Amgen, One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
AstraZeneca, Human Factors Engineering, BioPharmaceutical Development, Biopharmaceuticals R&D, 121 Oyster Point Blvd, South San Francisco, CA 94080, USA.
Adv Drug Deliv Rev. 2024 Jun;209:115322. doi: 10.1016/j.addr.2024.115322. Epub 2024 Apr 26.
Subcutaneous (SC) drug delivery can be a safe, effective alternative to the traditional intravenous route of administration, potentially offering notable advantages for both patients and healthcare providers. The SC Drug Development & Delivery Consortium convened in 2018 to raise awareness of industry challenges to advance the development of patient-centric SC drug delivery strategies. The SC Consortium identified better understanding of patient preferences and perspectives as necessary to optimize SC product design attributes and help guide design decisions during SC product development. This manuscript provides a comprehensive overview of patient-centric factors for consideration in the SC drug delivery design and development process with the aim of establishing a foundation of existing knowledge for patient experiences related to SC drug delivery. This overview is informed by the outcomes of a multi-step survey of Consortium members and key pharmaceutical stakeholders. Framed in the context of the patient's treatment journey, the survey findings offer future perspectives to fill data gaps to advance patient-centric SC drug delivery.
皮下（SC）药物给药可以作为传统静脉给药途径的安全、有效的替代方法，可能为患者和医疗保健提供者带来显著优势。2018 年，SC 药物开发和给药联盟召开会议，旨在提高对行业挑战的认识，以推进以患者为中心的 SC 药物给药策略的发展。SC 联盟确定，更好地了解患者的偏好和观点对于优化 SC 产品设计属性以及在 SC 产品开发过程中帮助指导设计决策是必要的。本文稿全面概述了在 SC 药物输送设计和开发过程中需要考虑的以患者为中心的因素，旨在为与 SC 药物输送相关的患者体验建立现有知识基础。这一概述是通过对联盟成员和主要制药利益相关者的多步骤调查的结果得出的。调查结果从患者治疗旅程的角度出发，为填补数据空白以推进以患者为中心的 SC 药物输送提供了未来展望。
